The ClinicianThe ClinicianКлиницист1818-83382412-8775Publishing House ABV Press13210.17650/1818-8338-2011-1-18-23ORIGINAL INVESTIGATIONSОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕASSOCIATION OF HIGH LIPOPROTEIN(a) LEVELS WITH CORONARY ARTERY PATENCY DURING THE FIRST YEAR AFTER PERCUTANEOUS CORONARY INTERVENTIONSСВЯЗЬ ВЫСОКОГО УРОВНЯ ЛИПОПРОТЕИДА(а) С ПРОХОДИМОСТЬЮ КОРОНАРНЫХ АРТЕРИЙ В ТЕЧЕНИЕ ПЕРВОГО ГОДА ПОСЛЕ ЧРЕСКОЖНЫХ КОРОНАРНЫХ ВМЕШАТЕЛЬСТВEzhovM. V.ЕжовМ. В.Russian Federationmarat_ezhov@mail.ruSafarovaM. S.СафароваМ. С.Russian FederationMatchinYu. G.МатчинЮ. Г.Russian FederationSobolevaD. I.СоболеваД. И.Russian FederationAfanasyevaO. I.АфанасьеваО. И.Russian FederationPokrovskyS. N.ПокровскийС. Н.Russian FederationRussian Cardiology Research Center, Institut of Clinical Cardiology, Ministry of Health and Social Development of the Russian FederationФГУ РКНПК Минздравсоцразвития РФ150120115118231807201418072014Copyright ©; 2011, Ezhov M.V., Safarova M.S., Matchin Y.G., Soboleva D.I., Afanasyeva O.I., Pokrovsky S.N.Copyright ©; 2011, Ежов М.В., Сафарова М.С., Матчин Ю.Г., Соболева Д.И., Афанасьева О.И., Покровский С.Н.2011Ezhov M.V., Safarova M.S., Matchin Y.G., Soboleva D.I., Afanasyeva O.I., Pokrovsky S.N.Ежов М.В., Сафарова М.С., Матчин Ю.Г., Соболева Д.И., Афанасьева О.И., Покровский С.Н.https://creativecommons.org/licenses/by/4.0https://klinitsist.abvpress.ru/Klin/article/view/132coronary heart diseaserisk factorslipoprotein(a)percutaneous coronary interventionsprogression of atherosclerosisrestenosisишемическая болезнь сердцафакторы рискалипопротеид(а)чрескожные коронарные вмешательствапрогрессирование атеросклерозарестеноз[1. Kamstrup P.R., Benn M., Tybjaerg-Hansen A., Nordestgaard B.G. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population. The Copenhagen City Heart Study. Circulation 2008;117:176–84.Kamstrup P.R., Benn M., Tybjaerg-Hansen A., Nordestgaard B.G. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population. The Copenhagen City Heart Study. Circulation 2008;117:176–84.][2. Clarke R., Peden J.F., Hopewell J.C., et al; PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;361(26):2518–28.Clarke R., Peden J.F., Hopewell J.C., et al; PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;361(26):2518–28.][3. Erqou S., Thompson A., Di Angelantonio E., et al. Apolipoprotein(a) isoforms and the risk ofErqou S., Thompson A., Di Angelantonio E., et al. Apolipoprotein(a) isoforms and the risk of][vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol][2010;55(19):2160–7.;55(19):2160–7.][4. MacLean J.W., Tomlinson J.E., Kuang W.J., et al. cDNA Sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330:132–7.MacLean J.W., Tomlinson J.E., Kuang W.J., et al. cDNA Sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330:132–7.][5. Curtis J.P, Schreiner G., Wang Y., et al. All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of medicare patients.JAm Coll Cardiol 2009;54:903–7.Curtis J.P, Schreiner G., Wang Y., et al. All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of medicare patients.JAm Coll Cardiol 2009;54:903–7.][6. Desmarais R.L., Sarembock I.J., Ayers C.R., et al. Elevated serum Lp(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995;91:1403–9.Desmarais R.L., Sarembock I.J., Ayers C.R., et al. Elevated serum Lp(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995;91:1403–9.][7. Kamitani T., Taniguchi T., Miyai N., et al. Association between plasma lipoprotein(a) concentration and restenosis after stent implantation. Circ J 2005;69:644–9.Kamitani T., Taniguchi T., Miyai N., et al. Association between plasma lipoprotein(a) concentration and restenosis after stent implantation. Circ J 2005;69:644–9.][8. Alaigh P., Hoffman C.J., Korlipara G., et al. Lipoprotein(a) level does not predict restenosis after percutaneous transluminal coronary angioplasty. Arterioscler Thromb Vasc Biol 1998;18:1281–6.Alaigh P., Hoffman C.J., Korlipara G., et al. Lipoprotein(a) level does not predict restenosis after percutaneous transluminal coronary angioplasty. Arterioscler Thromb Vasc Biol 1998;18:1281–6.][9. Ribichini F., Steffenino G., Dellavalle A., et al. Plasma lipoprotein(a) is not a predictor forRibichini F., Steffenino G., Dellavalle A., et al. Plasma lipoprotein(a) is not a predictor for][restenosis after elective high-pressure coronary stenting. Circulation 1998;98:1172–7.][10. Wehinger A., Kastrati A., Elezi S., et al. Lipoprotein (a) and coronary thrombosis and restenosis after stent placement. J Am Coll Cardiol 1999;33:1005–12.Wehinger A., Kastrati A., Elezi S., et al. Lipoprotein (a) and coronary thrombosis and restenosis after stent placement. J Am Coll Cardiol 1999;33:1005–12.][11. Zairis M.N., Ambrose J.A., Manousakis S.J., et al. The impact of plasma levels of C-reactiveZairis M.N., Ambrose J.A., Manousakis S.J., et al. The impact of plasma levels of C-reactive][protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary][stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study.][J Am Coll Cardiol 2002;40:1375–82.][12. Gazzaruso C., Garzaniti A., Falcone C., et al. Restenosis after intracoronary stent placement:Gazzaruso C., Garzaniti A., Falcone C., et al. Restenosis after intracoronary stent placement:][can apolipoprotein(a) polymorphism play a role? Int J Cardiol 2003;87:91–8.][13. Matsumoto Y., Daida H., Watanabe Y., et al. High level of lipoprotein(a) is a strong predictor for progression of coronary artery disease. J Atheroscler Thromb 1998;5:47–53.Matsumoto Y., Daida H., Watanabe Y., et al. High level of lipoprotein(a) is a strong predictor for progression of coronary artery disease. J Atheroscler Thromb 1998;5:47–53.][14. Igarashi Y., Aizawa Y., Satoh T., et al. Predictors of adverse long-term outcome in acute myocardial infarction patients undergoing primary percutaneous transluminal coronary angioplasty: with special reference to the admission concentration of lipoprotein(a). Circ J 2003;67:605–11.Igarashi Y., Aizawa Y., Satoh T., et al. Predictors of adverse long-term outcome in acute myocardial infarction patients undergoing primary percutaneous transluminal coronary angioplasty: with special reference to the admission concentration of lipoprotein(a). Circ J 2003;67:605–11.][15. Uchida T., Inoue T., Kamishirado H., et al. Prediction of short-term progression or regression of atherosclerotic coronary artery disease by lipoprotein(a): a quantitative coronary angiographic study. Angiology 2003;54:641–6.Uchida T., Inoue T., Kamishirado H., et al. Prediction of short-term progression or regression of atherosclerotic coronary artery disease by lipoprotein(a): a quantitative coronary angiographic study. Angiology 2003;54:641–6.][16. Morita Y., Himeno H., Yakuwa H., Usui T. Serum lipoprotein(a) level and clinical coronary stenosis progression in patients with myocardial infarction: re-revascularization rate is high in patients with high-Lp(a). Circ J 2006;70:156–62.Morita Y., Himeno H., Yakuwa H., Usui T. Serum lipoprotein(a) level and clinical coronary stenosis progression in patients with myocardial infarction: re-revascularization rate is high in patients with high-Lp(a). Circ J 2006;70:156–62.][17. Terres W., Tatsis E., Pfalzer B., et al. Rapid angiographic progression of coronary heart disease in patients with elevated lipoprotein(a). Circulation 1995;91:948–50.Terres W., Tatsis E., Pfalzer B., et al. Rapid angiographic progression of coronary heart disease in patients with elevated lipoprotein(a). Circulation 1995;91:948–50.][18. Hartmann M., von Birgelen C., Mintz G., et al. Relation between lipoprotein(a) and fibrinogen and serial intravascular ultrasound plaque progression in left main coronary arteries. J Am Coll Cardiol 2006;48:446–52.Hartmann M., von Birgelen C., Mintz G., et al. Relation between lipoprotein(a) and fibrinogen and serial intravascular ultrasound plaque progression in left main coronary arteries. J Am Coll Cardiol 2006;48:446–52.][19. Афанасьева О.И., Адамова И.Ю., Беневоленская Г.Ф., Покровский С.Н. Иммуноферментный метод определения липопротеида(а). Бюллетень экспериментальной биологии и медициныАфанасьева О.И., Адамова И.Ю., Беневоленская Г.Ф., Покровский С.Н. Иммуноферментный метод определения липопротеида(а). Бюллетень экспериментальной биологии и медицины][1995;4:398–401.;4:398–401.][20. Austen G.W., Edwards J.E., Frye R.L., et al. A reporting system on patients evaluated for coronary heart disease. Circulation 1975;51:5–40.Austen G.W., Edwards J.E., Frye R.L., et al. A reporting system on patients evaluated for coronary heart disease. Circulation 1975;51:5–40.][21. Smith S.C. Jr., Dove J.T., Jacobs A.K., et al. АСС/АНА Guidelines for percutaneous сoronary intervention (revision of the 1993 PTCA Guidelines) – executive summary. A Report of the American College of Cardiology/American Heart Association Task Forse on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001;103:3019–41.Smith S.C. Jr., Dove J.T., Jacobs A.K., et al. АСС/АНА Guidelines for percutaneous сoronary intervention (revision of the 1993 PTCA Guidelines) – executive summary. A Report of the American College of Cardiology/American Heart Association Task Forse on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001;103:3019–41.][22. Beatt К., Serruys P., Rensing В., Hugenoltz P. Restenosis after coronary angioplasty: New standard of clinical studies. J Am Coll Cardiol 1990;15:491–8.Beatt К., Serruys P., Rensing В., Hugenoltz P. Restenosis after coronary angioplasty: New standard of clinical studies. J Am Coll Cardiol 1990;15:491–8.][23. Lloyd G.W., Jackson G., Foley D.P., et al. The influence of plasma lipoprotein(a) on angiographic restenosis and coronary events in patients undergoing planned coronary balloon angioplasty. Ancillary analysis of the Fluvastatin Angioplasty Restenosis (FLARE) trial. Atherosclerosis 2001;158:445–54.Lloyd G.W., Jackson G., Foley D.P., et al. The influence of plasma lipoprotein(a) on angiographic restenosis and coronary events in patients undergoing planned coronary balloon angioplasty. Ancillary analysis of the Fluvastatin Angioplasty Restenosis (FLARE) trial. Atherosclerosis 2001;158:445–54.][24. Grainger D.J., Kemp P.R., Liu A.C., et al. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature 1994;370:460–2.Grainger D.J., Kemp P.R., Liu A.C., et al. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature 1994;370:460–2.][25. Lawn R.M., Pearle A.D., Kunz L.L., et al. Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice. J Biol Chem 1996;271:31367–71.Lawn R.M., Pearle A.D., Kunz L.L., et al. Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice. J Biol Chem 1996;271:31367–71.][26. Etingin O.R, Hajjar D.P, Hajjar K.A., et al. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 1991;266:2459–65.Etingin O.R, Hajjar D.P, Hajjar K.A., et al. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 1991;266:2459–65.][27. Daida H., Lee Y.J., Yokoi H., et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA) by reducing lipoprotein(a) levels with low-density lipoprotein apheresis. Low-Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group. Am J Cardiol 1994;73:1037–40.Daida H., Lee Y.J., Yokoi H., et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA) by reducing lipoprotein(a) levels with low-density lipoprotein apheresis. Low-Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group. Am J Cardiol 1994;73:1037–40.]